Recently updated clinical guidelines have highlighted the gaps in our understanding and management of pediatric hypertension. With increased recognition and diagnosis of pediatric hypertension, the use of antihypertensive agents is also likely to increase. Drug selection to treat hypertension in the pediatric patient population remains challenging. This is primarily due to a lack of large, well-designed pediatric safety and efficacy trials, limited understanding of pharmacokinetics in children, and unknown risk of prolonged exposure to antihypertensive therapies. With newer legislation providing financial incentives for conducting clinical trials in children, along with publication of pediatric-focused guidelines, literature available for antihypertensive agents in pediatrics has increased over the last 20 years. The objective of this article is to review the literature for safety and efficacy of commonly prescribed antihypertensive agents in pediatrics. Thus far, the most data to support use in children was found for angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), and calcium channel blockers (CCB). Several gaps were noted in the literature, particularly for beta blockers, vasodilators, and the long-term safety profile of antihypertensive agents in children. Further clinical trials are needed to guide safe and effective prescribing in the pediatric population.
Limited pharmacokinetic and safety data exist for MMF in pediatric HTR. Previously targeted MPA-TL are 1.5-3.0 μg/mL. The objective of this study was to assess the outcomes targeting MPA-TL of 0.8-2.0 μg/mL in pediatric HTR. MPA-TL were retrospectively collected 2-12 months post-transplant. Acute rejection, infection, leukopenia, and GI complaints were then correlated with MPA-TL. A total of 355 MPA-TL from 22 HTR were included. Median age was 2.5 yr. Primary indication for transplant was dilated cardiomyopathy (64%). Mean MPA-TL was 1.7 ± 0.9 μg/mL. African American patients received significantly higher doses (702 ± 235 mg/m(2) ) compared with other races (p = 0.035). Leukopenia was less common in patients with SUB MPA vs. others (p = 0.01). MMF was discontinued for GI complaints in one patient and leukopenia in two patients. One SUB patient had acute rejection, and one SUP patient had infection. One-yr survival was 100%. Targeting a lower range for MPA-TL was not associated with significant rejection or infection. Despite lower MPA-TL, MMF was discontinued in 3/22 patients for adverse effects.
Background. Continuous-flow left ventricular assist devices have revolutionized the management of advanced heart failure. Device complications continue to limit survival, but enhanced management strategies have shown promise. This study compared outcomes for HeartMate II recipients before and after implementation of a multidisciplinary continuous support heart team (HTMCS) strategy. Methods. Between January 2012 and December 2016, 124 consecutive patients underwent primary HeartMate II implantation at our institution. In January 2015, we instituted a HTMCS approach consisting of (1) daily simultaneous cardiology/cardiac surgery/critical care/ pharmacy/coordinator rounds, (2) pharmacist-directed anticoagulation, (3) speed optimization echocardiogram before discharge, (4) comprehensive device thrombosis screening and early intervention, (5) blood pressure clinic with pulsatility-adjusted goals, (6) early follow-up after discharge and individual long-term coordinator/cardiologist assignment, and (7) systematic basic/advanced/ expert training and credentialing of ancillary in-hospital providers. All patients completed 1-year of follow-up. Results. Demographic characteristics for pre-HTMCS (n [ 71) and HTMCS (n [ 53) groups, including age (55.8 ± 12.1 versus 52.5 ± 14.1 years, p [ not significant), percentage of men (77.5% versus 71.7%, p [ not significant), and Interagency Registry for Mechanically Assisted Circulatory Support class 3 (84.5% versus 83.0%, p [ not significant), were comparable. One-year survival was 74.6% versus 100% for the pre-HTMCS and HTMCS groups, respectively (p [ 0.0002). One-year survival free of serious adverse events (reoperation to replace device or disabling stroke) was 70.4% versus 84.9% for the pre-HTMCS and HTMCS groups, respectively (p [ 0.059). Event per patient-year rates for disabling stroke (0.15 versus 0, p [ 0.019), gastrointestinal bleeding (0.87 versus 0.51, p [ 0.11), and driveline infection (0.24 versus 0.10, p [ 0.18) were lower for the HTMCS group, whereas pump thrombosis requiring device exchange was higher (0.09 versus 0.18, p [ 0.14). Conclusions. Implementing a comprehensive multidisciplinary approach substantially improved outcomes for recipients of continuous-flow left ventricular assist devices.
Rabbit anti-thymocyte globulin (rATG) has proven benefit as induction therapy in renal transplant recipients, achieving reduced acute rejection rates and better short-term allograft function, with slightly higher rates of complications such as infections and malignancy. Compared with other agents, the most benefit from rATG induction has been observed in renal transplant recipients at high immunologic risk for rejection. However, in special populations, such as pediatrics, the elderly, and hepatitis C-positive and human immunodeficiency virus-positive renal transplant recipients, additional information is needed to delineate the absolute benefit of rATG induction compared with other induction agents. Selection of rATG as the choice of induction therapy in renal transplant recipients should be guided by a cost-effective approach in balancing efficacy, safety, and cost. This review summarizes the published literature on efficacy, safety, and cost of rATG induction in renal transplantation.
Upon tacrolimus dose increases, discontinuation of carbamazepine, and minimization of phenobarbital dose, effective tacrolimus trough levels were achieved in our patient. Identification and elimination of such drug-drug interactions is necessary to assure adequate immunosuppression in renal transplant recipients.
however dose reductions (DR) secondary to adverse effects (AE) are often required. The outcomes of MMF DR in OHT recipients have not yet been examined. We sought to determine the frequency of MMF DR within the first year post-OHT, and evaluate incidence of AE and biopsy-proven acute rejection (BPAR) in patients receiving full versus reduced dose MMF. Methods: Patients transplanted between May 2009 and October 2014 were retrospectively reviewed. MMF dose, rationale for dose change, and white blood cell counts (WBC) were recorded at time of hospital discharge, 3, 6, and 12 months post-OHT. Incidences of infection requiring treatment, leukopenia (WBC less than 3 cells/mm 3), gastrointestinal (GI) complaints (nausea, vomiting, diarrhea) and BPAR (≥ grade 2R/3A) were then correlated with MMF dose. Standard immunosuppression included tacrolimus and prednisone as well. Results: 86 patients were included in this study. The mean age at time of OHT was 56 ± 12 years; 76% of the patients were male. The mean MMF dose and WBC at discharge was 2470 ± 666 mg/day and 11 ± 4.3 cells/mm 3 , respectively. The mean MMF doses at month 3, 6, and 12 post-OHT were 1928 ± 920 mg/day, 1560 ± 984 mg/day, and 1560 ± 890 mg/day, respectively. At least one or more MMF DR occurred in 75/86 (87%) patients, with the highest percent DR between months 0 and 3. The primary indication for DR was leukopenia (60%). At 12 months, patients with persistent leukopenia required significantly lower mean MMF doses than those with transient leukopenia (467 ± 372 mg vs. 975 ± 325 mg, p= 0.0001). MMF DR occurred in 2 patients for GI complaints and in 11 patients due to infection. There were 6 incidences of ≥ 2R/3A rejection; 4 patients were on MMF 3 grams/day, 1 patient was on 2grams/day, and 1 patient was off MMF. Conclusion: Conventional MMF dosing of 3grams/day was poorly tolerated in our patients. When utilized as part of a standard immunosuppression regimen, a lower initial MMF dose may limit AE and decrease pill burden while still maintaining acceptable patient and graft outcomes. Further prospective studies are needed.
No abstract
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.